{ "schemaVersion": 1, "organisationId": "O-2e395e65836a4bb18a817f57457d11da", "slug": "acadia-pharmaceuticals-inc", "name": "ACADIA PHARMACEUTICALS INC", "updatedAt": "2026-10-02T14:00:41.147591Z", "sections": [ { "type": "OVERVIEW", "text": "Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing treatments for neurological disorders and rare diseases. Its products include NUPLAZID (pimavanserin), for hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE (trofinetide), for Rett syndrome. [P117094349] Acadia describes its mission as turning scientific promise into meaningful innovation for people with neurological disorders and rare diseases, particularly in underserved communities. [https://acadia.com/en-us/about/corporate-responsibility]\n\nThe company reported $1,071.5 million in total revenue for 2025. [T429910] Acadia’s corporate fact sheet lists more than 900 employees and offices in the United States, Canada, Switzerland, and the Netherlands. [https://acadia.com/en-us/pdf/media/us-corporate-fact-sheet.pdf] Founded in 1993, the company rebranded as Acadia Pharmaceuticals in 1997. [https://acadia.com/en-us/about/history]\n[P117094349][T429910][https://acadia.com/en-us/about/corporate-responsibility][https://acadia.com/en-us/pdf/media/us-corporate-fact-sheet.pdf][https://acadia.com/en-us/about/history]", "updatedAt": "2026-10-02T14:00:41.147591Z" }, { "type": "PRODUCTS", "text": "Acadia’s commercial products include NUPLAZID (pimavanserin), approved in the United States for hallucinations and delusions associated with Parkinson’s disease psychosis. It is supplied as 10 mg tablets and 34 mg capsules. [P146200354] [P146200871] DAYBUE (trofinetide) is approved for Rett syndrome and is available as an oral solution and as DAYBUE STIX, a powder stick-pack formulation launched in the U.S. in the second quarter of 2026; reported pack sizes are 5 g, 6 g, and 8 g. [P146200354] [P146200871] In the European Union, trofinetide is approved under the name DAYBU for neurobehavioral symptoms of Rett syndrome in adults and children aged 5 and older. [https://acadia.com/en-us/media/news-releases/european-commission-approves-daybu-trofinetide-as-the-first-and-only-treatment-for-neurobehavioral-symptoms-of-rett-syndrome-in-the-european-union]\n\nFor the six months ended June 30, 2026, NUPLAZID net sales were $350.1 million and DAYBUE product sales were $226.0 million, equivalent to approximately 60.8% and 39.2% of reported total revenue, respectively. [P146200391] [P146200333] Acadia also offers patient and family support through Acadia Connect, including treatment education and assistance navigating insurance and potential financial assistance for DAYBUE, as well as patient-support resources for NUPLAZID. [https://daybue.com/treatment-support/] [https://www.nuplazid.com/acadia-connect-patient-support]\n[P146200354][P146200871][P146200391][P146200333][https://acadia.com/en-us/media/news-releases/european-commission-approves-daybu-trofinetide-as-the-first-and-only-treatment-for-neurobehavioral-symptoms-of-rett-syndrome-in-the-european-union][https://daybue.com/treatment-support/][https://www.nuplazid.com/acadia-connect-patient-support]", "updatedAt": "2026-10-02T14:00:41.147591Z" }, { "type": "GEOGRAPHY", "text": "Acadia Pharmaceuticals’ principal executive office is in San Diego, California, where it also maintains a roughly 67,000-square-foot primary office facility. Its Princeton, New Jersey office lease commenced in the second quarter of 2026; the company’s contact page also lists an office in South San Francisco, California. [T12343460][P72038232][P146200326][https://acadia.com/en-us/contact]\n\nThe company announced that DAYBUE became commercially available in the United States in April 2023. Its filings report product sales but do not disclose revenue by country or region, or employees by location. Acadia uses third-party manufacturers, but the filings reviewed do not identify the locations of their manufacturing sites. [https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-daybuetm-trofinetide-now][P12228174][P146200871]\n[T12343460][P72038232][P146200326][P12228174][P146200871][https://acadia.com/en-us/contact][https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-daybuetm-trofinetide-now]", "updatedAt": "2026-10-02T14:00:41.147591Z" }, { "type": "SEGMENTS", "text": "ACADIA reports one operating and reportable segment: the development and commercialization of innovative medicines. NUPLAZID and DAYBUE are products within that segment, not separately reported segments. [P43327965]\n\nFor the three months ended March 31, 2026, product sales were $166.9 million for NUPLAZID and $101.2 million for DAYBUE—approximately 62% and 38%, respectively, of their combined sales. These are product-sales proportions, not an official segment contribution breakdown. NUPLAZID is approved for hallucinations and delusions associated with Parkinson’s disease psychosis; DAYBUE is approved for Rett syndrome. [P25170218][P120708295]\n[P43327965][P25170218][P120708295]", "updatedAt": "2026-10-02T14:00:41.147591Z" }, { "type": "HISTORY", "text": "Acadia Pharmaceuticals was founded in 1993 in Winooski, Vermont, as Receptor Technologies, by University of Vermont professor Mark Brann. It reincorporated in Delaware in 1997 and completed its initial public offering in 2004, beginning trading on Nasdaq as ACAD. [https://acadia.com/en-us/about/history] [P33291436] [https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-initial-public-offering]\n\nA major milestone came in 2016, when the FDA approved NUPLAZID (pimavanserin) for hallucinations and delusions associated with Parkinson’s disease psychosis; Acadia launched the medicine in the United States that year. [https://acadia.com/en-us/media/news-releases/fda-approves-acadia-pharmaceuticals-nuplazidtm-pimavanserin] [P35920690] In 2018, Acadia obtained North American development and commercialization rights to trofinetide from Neuren Pharmaceuticals. [P18238513] It acquired CerSci Therapeutics in 2020, adding an investigational non-opioid pain program. [https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-acquires-cersci-therapeutics-adds-novel]\n\nIn 2023, the FDA approved DAYBUE (trofinetide) for Rett syndrome, and Acadia expanded its agreement with Neuren to include rights outside North America for trofinetide and global rights to NNZ-2591 for Rett and Fragile X syndromes. [https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-us-fda-approval-daybuetm] [P10845343] [P108818556] Catherine Owen Adams succeeded Steve Davis as CEO in 2024. [P114170678]\n[https://acadia.com/en-us/about/history][P33291436][https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-initial-public-offering][https://acadia.com/en-us/media/news-releases/fda-approves-acadia-pharmaceuticals-nuplazidtm-pimavanserin][P35920690][P18238513][https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-acquires-cersci-therapeutics-adds-novel][https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-us-fda-approval-daybuetm][P10845343][P108818556][P114170678][https://acadia.com/en-us/about/history][https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-initial-public-offering][https://acadia.com/en-us/media/news-releases/fda-approves-acadia-pharmaceuticals-nuplazidtm-pimavanserin][https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-acquires-cersci-therapeutics-adds-novel][https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-us-fda-approval-daybuetm]", "updatedAt": "2026-10-02T14:00:41.147591Z" } ], "sources": [ { "id": "P117094349", "href": "https://app.finbar.com/go?id=P117094349", "label": "ACADIA PHARMACEUTICALS INC — Full financial report (2026 Q 1)", "documentId": "D-be9da8b0d0de4ba8bd6ebb7058482114" }, { "id": "https://acadia.com/en-us/about/corporate-responsibility", "href": "https://acadia.com/en-us/about/corporate-responsibility", "label": "acadia.com" }, { "id": "T429910", "href": "https://app.finbar.com/go?id=T429910", "label": "ACADIA PHARMACEUTICALS INC — Full financial report (2025 Y)", "documentId": "D-03b6e7a08fe244409e256c2134808860" }, { "id": "https://acadia.com/en-us/pdf/media/us-corporate-fact-sheet.pdf", "href": "https://acadia.com/en-us/pdf/media/us-corporate-fact-sheet.pdf", "label": "acadia.com" }, { "id": "https://acadia.com/en-us/about/history", "href": "https://acadia.com/en-us/about/history", "label": "acadia.com" }, { "id": "P146200354", "href": "https://app.finbar.com/go?id=P146200354", "label": "ACADIA PHARMACEUTICALS INC — Full financial report (2026 Q 2)", "documentId": "D-848f943b45704332abfaff82557a0ff7" }, { "id": "P146200871", "href": "https://app.finbar.com/go?id=P146200871", "label": "ACADIA PHARMACEUTICALS INC — Full financial report (2026 Q 2)", "documentId": "D-848f943b45704332abfaff82557a0ff7" }, { "id": "https://acadia.com/en-us/media/news-releases/european-commission-approves-daybu-trofinetide-as-the-first-and-only-treatment-for-neurobehavioral-symptoms-of-rett-syndrome-in-the-european-union", "href": "https://acadia.com/en-us/media/news-releases/european-commission-approves-daybu-trofinetide-as-the-first-and-only-treatment-for-neurobehavioral-symptoms-of-rett-syndrome-in-the-european-union", "label": "acadia.com" }, { "id": "P146200391", "href": "https://app.finbar.com/go?id=P146200391", "label": "ACADIA PHARMACEUTICALS INC — Full financial report (2026 Q 2)", "documentId": "D-848f943b45704332abfaff82557a0ff7" }, { "id": "P146200333", "href": "https://app.finbar.com/go?id=P146200333", "label": "ACADIA PHARMACEUTICALS INC — Full financial report (2026 Q 2)", "documentId": "D-848f943b45704332abfaff82557a0ff7" }, { "id": "https://daybue.com/treatment-support/", "href": "https://daybue.com/treatment-support/", "label": "daybue.com" }, { "id": "https://www.nuplazid.com/acadia-connect-patient-support", "href": "https://www.nuplazid.com/acadia-connect-patient-support", "label": "www.nuplazid.com" }, { "id": "T12343460", "href": "https://app.finbar.com/go?id=T12343460", "label": "ACADIA PHARMACEUTICALS INC — Full financial report (2025 Y)", "documentId": "D-03b6e7a08fe244409e256c2134808860" }, { "id": "P72038232", "href": "https://app.finbar.com/go?id=P72038232", "label": "ACADIA PHARMACEUTICALS INC — Full financial report (2025 Y)", "documentId": "D-03b6e7a08fe244409e256c2134808860" }, { "id": "P146200326", "href": "https://app.finbar.com/go?id=P146200326", "label": "ACADIA PHARMACEUTICALS INC — Full financial report (2026 Q 2)", "documentId": "D-848f943b45704332abfaff82557a0ff7" }, { "id": "https://acadia.com/en-us/contact", "href": "https://acadia.com/en-us/contact", "label": "acadia.com" }, { "id": "https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-daybuetm-trofinetide-now", "href": "https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-daybuetm-trofinetide-now", "label": "acadia.com" }, { "id": "P12228174", "href": "https://app.finbar.com/go?id=P12228174", "label": "ACADIA PHARMACEUTICALS INC — Full financial report (2025 Y)", "documentId": "D-03b6e7a08fe244409e256c2134808860" }, { "id": "P43327965", "href": "https://app.finbar.com/go?id=P43327965", "label": "ACADIA PHARMACEUTICALS INC — Full financial report (2026 Q 1)", "documentId": "D-be9da8b0d0de4ba8bd6ebb7058482114" }, { "id": "P25170218", "href": "https://app.finbar.com/go?id=P25170218", "label": "ACADIA PHARMACEUTICALS INC — Full financial report (2026 Q 1)", "documentId": "D-be9da8b0d0de4ba8bd6ebb7058482114" }, { "id": "P120708295", "href": "https://app.finbar.com/go?id=P120708295", "label": "ACADIA PHARMACEUTICALS INC — Full financial report (2026 Q 1)", "documentId": "D-be9da8b0d0de4ba8bd6ebb7058482114" }, { "id": "P33291436", "href": "https://app.finbar.com/go?id=P33291436", "label": "ACADIA PHARMACEUTICALS INC — Full financial report (2024 Y)", "documentId": "D-75c88ff5e7a146a6be8240afa92362b9" }, { "id": "https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-initial-public-offering", "href": "https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-initial-public-offering", "label": "acadia.com" }, { "id": "https://acadia.com/en-us/media/news-releases/fda-approves-acadia-pharmaceuticals-nuplazidtm-pimavanserin", "href": "https://acadia.com/en-us/media/news-releases/fda-approves-acadia-pharmaceuticals-nuplazidtm-pimavanserin", "label": "acadia.com" }, { "id": "P35920690", "href": "https://app.finbar.com/go?id=P35920690", "label": "ACADIA PHARMACEUTICALS INC — Full financial report (2024 Y)", "documentId": "D-75c88ff5e7a146a6be8240afa92362b9" }, { "id": "P18238513", "href": "https://app.finbar.com/go?id=P18238513", "label": "ACADIA PHARMACEUTICALS INC — Full financial report (2024 Y)", "documentId": "D-75c88ff5e7a146a6be8240afa92362b9" }, { "id": "https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-acquires-cersci-therapeutics-adds-novel", "href": "https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-acquires-cersci-therapeutics-adds-novel", "label": "acadia.com" }, { "id": "https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-us-fda-approval-daybuetm", "href": "https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-us-fda-approval-daybuetm", "label": "acadia.com" }, { "id": "P10845343", "href": "https://app.finbar.com/go?id=P10845343", "label": "ACADIA PHARMACEUTICALS INC — Full financial report (2024 Y)", "documentId": "D-75c88ff5e7a146a6be8240afa92362b9" }, { "id": "P108818556", "href": "https://app.finbar.com/go?id=P108818556", "label": "ACADIA PHARMACEUTICALS INC — Full financial report (2024 Y)", "documentId": "D-75c88ff5e7a146a6be8240afa92362b9" }, { "id": "P114170678", "href": "https://app.finbar.com/go?id=P114170678", "label": "ACADIA PHARMACEUTICALS INC — Full financial report (2024 Y)", "documentId": "D-75c88ff5e7a146a6be8240afa92362b9" } ] }